Vantage Consulting Group’s Fulgent Genetics FLGT Stock Holding History

Vantage Consulting Group’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-397	Closed	-$21K	–	621
2020 Q4	$21K	Buy	+397	New	+$16.6K	﹤0.01%	847

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Vantage Consulting Group's FLGT Position: Q1 2021 in Review

Vantage Consulting Group sold out of Fulgent Genetics (FLGT) in Q1 2021, closing a stake of 397 shares — an estimated $21K sold.

Vantage Consulting Group first reported a position in FLGT in Q4 2020 and held it in 1 quarter. The position peaked at $21K in Q4 2020. 256 funds tracked by Wall St. Rank hold FLGT as of Q1 2021.

Vantage Consulting Group reported no remaining Fulgent Genetics position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 397 Fulgent Genetics shares in Q1 2021, an estimated $21K.
Vantage Consulting Group first reported a position in Fulgent Genetics in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's Fulgent Genetics position peaked at $21K in Q4 2020.
256 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.